valsartan has been researched along with Debility in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, IS; Atar, D; Butt, JH; Desai, AS; Dewan, P; Echeverria, LE; Ge, J; Gong, J; Jhund, PS; Køber, L; Lam, CSP; Lefkowitz, MP; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Sim, D; Solomon, SD; Van Veldhuisen, DJ; Vrtovec, B; Zannad, F; Zile, MR | 1 |
1 trial(s) available for valsartan and Debility
| Article | Year |
|---|---|
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Frailty; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |